Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

This trial will enable patients with relapsed/refractory disease to receive glofitamab at an earlier line than is currently approved in the United States. Overall, it is anticipated that the benefits of glofitamab as a single agent will outweigh its potential risks, particularly given the poor prognosis of patients with relapsed/refractory DLBCL or MCL who have failed SoC regimens. Glofitamab offers high rates of complete response with durable disease control and favorable toxicity profile relative to current SoC regimens, such as chemotherapy or autologous stem cell transplantation.